Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Perry V Halushka

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology and Therapeutics|May 9, 2006
Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypesMarc K Halushka, Perry V Halushka
Circulation|April 10, 2002
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?Marc K Halushka, Perry V Halushka
Academic Medicine : Journal of the Association of American Medical Colleges|March 26, 2009
Is the training of biomedical scientists at a crossroads?Perry V Halushka, Edward L Krug
European Journal of Medicinal Chemistry|December 4, 2003
Hydrogen bond interactions of a series of N-substituted TXA2 receptor antagonistsDawne M Taylor, Perry V Halushka, G Patrick Meier
Clinical Pharmacology and Therapeutics|January 25, 2003
Genetic variation in cyclooxygenase 1: effects on response to aspirinMarc K Halushka, Linda P Walker, Perry V Halushka
CBE Life Sciences Education|February 13, 2015
The faculty costs to educate a biomedical sciences graduate studentAdam J Smolka, Perry V Halushka, Elizabeth Garrett-Mayer
FASEB Bioadvances|August 25, 2020
An impaired natriuretic peptide hormone system may play a role in COVID-19 severity in vulnerable populationsMark G Currie, Daniel P Zimmer, Perry V Halushka
Annual Review of Pathology|October 18, 2018
Opportunities for microRNAs in the Crowded Field of Cardiovascular BiomarkersPerry V Halushka, Andrew J Goodwin, Marc K Halushka
Prostaglandins & Other Lipid Mediators|October 11, 2011
Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoringOmar Moussa, Andrew Ciupek, Dennis K Watson, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2003
The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cellsNa Qiao, Denis Reynaud, Peter Demin, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology and Therapeutics|May 9, 2006
Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypesMarc K Halushka, Perry V Halushka
Circulation|April 10, 2002
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?Marc K Halushka, Perry V Halushka
Academic Medicine : Journal of the Association of American Medical Colleges|March 26, 2009
Is the training of biomedical scientists at a crossroads?Perry V Halushka, Edward L Krug
European Journal of Medicinal Chemistry|December 4, 2003
Hydrogen bond interactions of a series of N-substituted TXA2 receptor antagonistsDawne M Taylor, Perry V Halushka, G Patrick Meier
Clinical Pharmacology and Therapeutics|January 25, 2003
Genetic variation in cyclooxygenase 1: effects on response to aspirinMarc K Halushka, Linda P Walker, Perry V Halushka
CBE Life Sciences Education|February 13, 2015
The faculty costs to educate a biomedical sciences graduate studentAdam J Smolka, Perry V Halushka, Elizabeth Garrett-Mayer
FASEB Bioadvances|August 25, 2020
An impaired natriuretic peptide hormone system may play a role in COVID-19 severity in vulnerable populationsMark G Currie, Daniel P Zimmer, Perry V Halushka
Annual Review of Pathology|October 18, 2018
Opportunities for microRNAs in the Crowded Field of Cardiovascular BiomarkersPerry V Halushka, Andrew J Goodwin, Marc K Halushka
Prostaglandins & Other Lipid Mediators|October 11, 2011
Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoringOmar Moussa, Andrew Ciupek, Dennis K Watson, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2003
The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cellsNa Qiao, Denis Reynaud, Peter Demin, et al.
Pageof 6